Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study

EJNMMI Research

Table 1 Summary of the EORTC and PERCIMT response criteria

	EORTC	PERCIMT
CMR	Complete resolution of ¹⁸F-FDG uptake within the tumor volume	Complete resolution of all pre-existing¹⁸F-FDG avid lesions. No new, ¹⁸F-FDG avid lesions
PMR	Decrease in tumor SUV > 25% after more than 1 therapeutic cycle	Complete resolution of some pre-existing¹⁸F-FDG avid lesions. No new, ¹⁸F-FDG avid lesions
SMD	Increase in tumor SUV < 25% or decrease in SUV < 15%	Neither PMD nor PMR/CMR
PMD	Increase in tumor SUV > 25% or appearance of new lesions	≥ 4 new lesions of less than 1.0 cm in functional diameter or ≥ 3 new lesions between 1.0 and 1.5 cm in functional diameter or ≥ 2 new lesions of more than 1.5 cm in functional diameter

EORTC, European Organization for Research and Treatment of Cancer; PERCIMT, PET Response Evaluation Criteria for Immunotherapy; CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease; SUV, standardized uptake value